Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301597 · ClinicalTrials.gov registry record · Phase 2
NLA101 in Adults Receiving High Dose Chemotherapy for AML
A Phase 2 study, sponsored by Nohla Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT03301597 is a Phase 2 study that was terminated before completion, run by Nohla Therapeutics. The registered enrollment target is 146 participants.
The verdict
NCT03301597, a Phase 2 study, was terminated before completion, sponsored by Nohla Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.
Interventions
- BIOLOGICAL NLA101
- DRUG Standard of Care (SOC) chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2019-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03301597
The ClinicalTrials.gov registry entry for NCT03301597 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nohla Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NLA101 is the first listed.
NCT03301597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03301597 about?
NCT03301597 is a clinical study titled "NLA101 in Adults Receiving High Dose Chemotherapy for AML". Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.
What is the current status of trial NCT03301597?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2018-01-24. Estimated completion is 2019-03-18.
What interventions are being tested in trial NCT03301597?
The interventions under investigation include: NLA101 (BIOLOGICAL), Standard of Care (SOC) chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03301597?
This trial is sponsored by Nohla Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.